| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7718640 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
Mar, 2027
(2 years from now) | |
| US8338395 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
May, 2027
(3 years from now) | |
Aveed is owned by Endo Pharms Inc.
Aveed contains Testosterone Undecanoate.
Aveed has a total of 2 drug patents out of which 0 drug patents have expired.
Aveed was authorised for market use on 05 March, 2014.
Aveed is available in injectable;intramuscular dosage forms.
Aveed can be used as testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; primary hypogonadism (congenital or acquired); hypogonadotropic hypogonadism (congenital or acquired)..
The generics of Aveed are possible to be released after 08 May, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 05, 2017 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 05 March, 2014
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: INJECTABLE;INTRAMUSCULAR
AVEED family patents
